BC Innovations | Aug 8, 2018
Distillery Therapeutics


INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest inhibiting HSF1 could help treat T cell ALL. In human T cell ALL cell lines, an shRNA targeting HSF1 decreased cell growth compared with...
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BC Innovations | Jan 19, 2018
Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...
BC Innovations | Aug 29, 2017
Distillery Therapeutics


INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture and mouse studies suggest activating HSF1 could help treat ALS. In HEK cells or mouse neuroblastoma cell lines expressing TDP-43 with a point mutation (K145Q) that promotes TDP-43...
BC Innovations | Aug 24, 2017
Translation in Brief

Unclumping TDP-43

Two studies published in Nature Communications have identified different features of TDP-43 that promote its aggregation in neurodegenerative disorders, and point to different therapeutic strategies for preventing or dissolving the clumps. Aggregation of TAR DNA...
BC Week In Review | Jul 13, 2015
Company News

Cleveland BioLabs, Bioprocess Capital Ventures deal

Cleveland sold 75% of its equity stake in Incuron for about $3 million to Dr. Mikhail Mogutov, who is the chairman of Incuron. Mogutov has an option to purchase Cleveland’s remaining stake for $1 million....
BC Innovations | Mar 19, 2015
Distillery Therapeutics

Therapeutics: Heat shock transcription factor 1 (HSF1); MEK; proteasome

Cancer INDICATION: Cancer In vitro and mouse studies suggest promoting amyloidogenesis could help treat cancer. In multiple human cancer cell lines - but not normal cell lines - co-treatment with a MEK inhibitor and proteasome inhibitor increased...
BC Innovations | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX); heat shock protein 90 (Hsp90) In vitro and mouse studies suggest inhibiting MLL in combination with HSP90 could...
BC Innovations | Mar 6, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction; Alzheimer's disease (AD) Heat shock protein 90 (Hsp90) Mouse and in vitro studies suggest inhibiting Hsp90 could enhance cognitive function. In cultured primary...
BC Week In Review | Aug 12, 2013
Clinical News

intravenous CBL0137: Phase I started

Cleveland BioLabs said Incuron LLC JV (Moscow, Russia) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 10, 20, 30, 40, 50 and 62.5 mg/m 2 IV CBL0137 given on days 1, 8 and...
Items per page:
1 - 10 of 29